Ignite Creation Date:
2024-05-06 @ 1:01 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01718301
Status:
COMPLETED
Last Update Posted:
2015-07-09
First Post:
2012-10-25
Brief Title:
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon Ribavirin
Sponsor:
Anna Cruceta
Organization:
Fundacion Clinic per a la Recerca Biomédica
Study Overview
Official Title:
A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon Ribavirin Eudra CT2012-003984-23
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BOC-HIV
Brief Summary:
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day TID orally PO in combination with Peginterferon either alpha 2b or alpha 2a and Ribavirin in HIVHCV genotype 1 infected patients that failed to previous HCV therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-003984-23 | EUDRACT_NUMBER | None | None |